The coronavirus has sped up the globe. Cities and countries are implementing lockdown policies, closing businesses, canceling school and other activities. Many companies sent their employees on vacation.
These are all measures taken for the sake of “social distancing, a way to contain the virus until therapies and vaccines are available to stop it.
A lot of attention is being paid to drugs that the biopharmaceutical industry is developing to treat COVID-19. But these efforts can mask health care costs in the form of delays in the progress of experimental drugs for other diseases.
Since early March, at least nine biopharmaceutical companies have reported clinical trial disruptions due to the coronavirus pandemic. Such news is becoming more common as medical centers around the world focus their precious resources on treating people infected with the coronavirus.
We follow the events in the pharmaceutical world and adhere to the rules of hygiene.
Comments